Good morning, everybody. Welcome to Physitrack's Q4 earnings webcast. I'm Henrik Molin, and I'm the CEO and Co-founder of Physitrack. I'm joined by Charlotte Goodwin, our CFO. We're gonna start by just briefly mentioning that we won't be providing a background to the company on this call. If you're interested in a deeper dive, we recommend that you take a look at our Q2 webcast, which is available on physitrackgroup.com. Here is a little reminder of where we are time-wise in our company life cycle. Some updates there on 2022, so happy to leave that for you to peruse after this call. I'm gonna jump into the little summary of Q4 in short for those of you who are short on time and want to get back to your cup of coffee. The 12-month revenue growth was 153%, and the pro forma revenue growth was 36%. Nice organic growth in combination with M&A-driven growth. The size of the company is now over EUR 10 million in terms of annualized revenue for the first time, which is really nice to see. In terms of key events that we saw there, obviously we've seen the merger or the acquisition from this morning of PT Courses in the U.S. This is something that we are very excited about because moving into e-learning for physiotherapy is something that we had as part of our playbook since 2017, and this is a key component for strengthening our presence in the U.S. Very nice to see that, and we're gonna give some deeper comments on that later on in this call. In terms of other highlights, we've had a really nice time integrating Physiotools, and now we have aligned their operations completely with Physitrack's, and we've been able to draw on the firepower of this team of exceptionally talented individuals in building a one culture and one team. That's been very, very favorable to us and in terms of acceleration and the way that we run the business. On that note, we are upgrading some of the plumbing or the underlying framework for the systems underpinning Physitrack just to support this continued growth. Among other things, a new accounting system that can support us up to triple-digit million, if and when we reach that level, and obviously some of the other things in terms of development, infrastructure, and ways for us to be more efficient and effective when we look at new features and develop them for continued commercial success. Digging a little bit deeper into the quarter in terms of the business, just looking at the underlying growth numbers, so very, very strong. On the user side of things, we had a nice growth of the user base, but something that's very important to point out here, we're not a one-trick pony in terms of revenue generation. We don't only have to rely on a growing user base to grow revenue. We have a lot of interesting products in our portfolio, and something that is continuing to generate some very nice revenue is our Custom App range, where we can work closely with healthcare providers and personalize the journey for their patients. This is something that we indicated already in Q3 that is something that is accelerating, and the acceleration has been even more rapid in Q4 around this. It's an effect of this increased sophistication when it comes to digital products in our space that has led to this. Notably, patients and consumers have become more savvy when it comes to digital, and they're putting pressure on their healthcare providers to expand into that. We're more than happy to offer a top-of-the-line range of Custom Apps and other services to meet those expectations that are now upon us. Very interesting in terms of notable wins. Well, obviously the big win is the very wide variety of small to medium-sized exposure to custom apps that we've had. If we are to name something that stands out on the enterprise side, Children's Mercy Hospital, very notable American healthcare system, which was part of a big RFP that we won in Q4. Acceleration continues, and we're more than happy to be in this space because it is something that's expected to continue growth going forward. Few comments on the PT Courses acquisition that was announced early this morning, and as I indicated in my introduction, this is a space that we have been very keen on moving into ever since 2017. In the U.S. market, the home exercise prescription systems are usually bought in tandem with e-learning for physios. It's something that's part of the mandatory education for physiotherapists is to be part of something like this, and it's something that's usually sold in bundles. Not having access to those type of bundles in the U.S. market is something that has held us back a little bit, which is why it's been on the strategic agenda for several years, and it's something that we've indicated that we were keen on expanding into via M&A for the last few quarters. I'm very, very happy to have gotten this on board. This is a very healthy, intelligent company. It's one of the older companies in the space. They've done quite well in building this from nothing, similar to Physitrack with their entrepreneurial spirit, and this is a nice company. The acquisition premium was EUR 1.8 million. There's no earn-out, so that was a one-off payment. It's the equivalent of about 3x revenue. We expect some really interesting revenue effects off of this, both in terms of the PT Courses effect of having Physitrack customers come in and purchase continuing education. Most notably, when we penetrate the U.S. market with home exercise prescription and related products, we see that these bundles with e-learning are gonna be very significant for us in terms of gaining market share. We couldn't be happier with that, and we will see revenue effects both with PT Courses on a standalone basis from this, but most notably on the Physitrack SaaS side. I'm gonna hand over now to Charlotte Goodwin, our CFO, to talk through the financials more in detail. Over to you, Charlotte. Thank you very much, Henrik. I'll start the finances off here with an overview of the key financials. Year-to-date revenue for the 12 months ending November 2021 has more than doubled to EUR 7.7 million from EUR 3.1 million in the prior year. Some of this growth is due to the acquisitions of Physiotools, Rehabplus, and Fysiotest. On a pro forma basis, with the revenue from these entities included in the prior year comparators, revenue increased 36%, in excess of our medium-term organic growth target of 30%. Revenue for the quarter ended November was EUR 2.4 million, up 165% from the last year. Pro forma revenue growth in the quarter was 47%, which is in line with our previous messaging that now the impacts of COVID-19 have smoothed out. We expect revenue growth to be weighted towards the end of the calendar year, driven by our large customers' purchasing cycles. In the year, the Physitrack Group has delivered adjusted EBITDA of EUR 2.6 million, up 58% from the prior year, and this results in year-to-date adjusted EBITDA margins of 33%, down from 53% in the prior year. This fall is a result of the well-signaled impact of the recent acquisitions on the group's margins. Can we move through to the next slide? Looking now at a more detailed view of revenue. On the left here, you can see the year-to-date growth, both on an absolute and pro forma basis. On the right-hand side, we see revenue by quarter with strong growth delivered in both the SaaS and Virtual Care parts of the business. Moving through to the next slide. Looking now at profit. On the left-hand side, we have the 12-month EBITDA. Last year, we delivered EBITDA of EUR 1.6 million, and in the current year, this has fallen to EUR 1 million. Within this, there was EUR 1.6 million of non-recurring adjusting items, primarily relating to the IPO, but also some M&A costs. With these amounts stripped out, adjusted EBITDA was EUR 2.6 million, or an increase of 58% from last year. Adjusted EBITDA margins have fallen from 53% last year to 33% in the current year, as discussed earlier, due to the impact of acquisitions. Over the medium term, we expect these to rebound to our target EBITDA margins of 40%-45%. On the right here, we have adjusted EBITDA shown by quarter. This shows the EBITDA expanding as revenue grows and cost synergies are implemented. There was a drop in EBITDA in Q4 last year, as in preparation for the IPO, we built in the additional governance and compliance required to be a listed company. These costs are now built into the business's run rate, and consequently, there was no similar drop in Q4 of the current year. Through to the next slide. Now looking at cash. We opened the year with a net debt position of EUR 500,000. Adjusted EBITDA in the period generated EUR 2.6 million and was offset by a working capital movement of EUR 0.5 million and a further EUR 0.1 million of interest payments. The working capital movement was driven by calendar year renewals for enterprise customers, which are often billed one month in advance of renewal, particularly in Physiotools, and we expect this to unwind early next year. Intangible asset additions were EUR 1.6 million in the period and predominantly consisted of development of the SaaS platform, plus initial investment in a new Access virtual care product, which Henrik will speak about later. In order to ensure Physitrack can effectively scale, we reviewed our internal operating systems and made the decision to implement Chargebee, a subscription management and billing system, and NetSuite as our group-wide ERP system. There were some upfront capitalized bill feeds in the year related to these, which will continue into the first half of next year. The largest item here on cash is, of course, the cash generated by the IPO, shown here net of the fees incurred. At the year-end, EUR 2.7 million of this cash had been utilized to fund acquisition consideration payments and M&A related costs. This leaves the group with a strong cash position of EUR 14.3 million to invest in future M&A activity. Through to the next slide. This is a summarized position of the group's balance sheet. The first line here includes the internally developed technology platform, as well as the intangible assets and goodwill arising on acquisitions. This figure now includes the accounting for our Fysiotest acquisition. The accounting for our most recent acquisition announced this morning will be included in the Q1 2022 numbers. Cash, as we've already spoken about, has increased due to the IPO proceeds, and borrowings have been repaid with these pro-proceeds. Trade and other receivables have increased due to the recent acquisitions, as well as the relative increase of our enterprise customer base and high levels of billings towards the end of the year. Deferred revenue is primarily generated by Physiotools, who bill up front for 12-month contracts. Deferred consideration relates to the Rehabplus and Fysiotest acquisitions. Just a quick piece of housekeeping here. As we previously announced, in order to align our financial year-end with our customers' purchasing cycles, the board has made the decision to change our year-end from November to December. We'll be shortly releasing an interim report for the three months ended December 2021 to align with the new year-end, alongside a 13-month annual report. All key dates related to this have been updated in the financial calendar on our website. That's all from me on the financials. Of course, feel free to ask any questions in the Q&A portion, but for now, I'll pass you back to Henrik. Thank you, Charlotte. Just a few slides here in terms of the strategy and outlook. We will reiterate here, on the left side there, market growth dynamics continue to be favorable. We are in the middle of really nice macro tailwinds. We spoke about the trends for small to mid-size providers to invest in technology, as well and becoming more advanced following pressure from consumers to step things up. That's a trend that we see continuing across our market space. Obviously on the enterprise side, we see a lot of RFP activity, we see a lot of investments into the space, and this will continue to be quite favorable. Now, in the middle there, organic growth levers. We are just in the beginning of digitization of emerging markets, for example, and we have nice presence there. We had some notable wins in places like Indonesia in the quarter, and that's an indication that this is something that is about to take off. We're quite happy there with the exposure that we have to these markets, and we can expect more activity there in the future as we move forward. On the M&A side, we continue to see some very interesting opportunities with some great entrepreneurs that can come in with healthy, fast-growing standalone businesses that can also fertilize what we do with the rest of the business. We are happy to continue this activity, and we feel that the targeted, on average, one M&A transaction a quarter. This continues to be achievable. This is a very, very exciting time to be in the space, because there are some really, really nice opportunities out there. Just a quick view ahead in terms of what we're doing product development side-wise. We are introducing new SaaS-based products for our care providing subsidiaries, Rehabplus and Fysiotest. Rehabplus in the U.K., Fysiotest in Sweden, and this is based on existing Physitrack technology that has been enhanced to be a holistic care product on a subscription model that gives employers access to health and wellness and rehabilitation products for emotional well-being and for physical well-being. It's a product that we are slowly releasing here in Q1, starting in the Nordics. This is something that allows providers to tailor a digital journey for employers in a preventive way for emotional well-being and physical well-being. We come in and assess a company with employee questionnaires and also blood testing with IP from Fysiotest, which has been very successful with great growth. We calibrate our offering for the individual companies and the employees. You launch widely, and then you reassess based on the actual results that come in. For the individual employee, it is a personalized journey that is underpinned by great technology and great humans that work with the technology to make sure that you have a journey that fits for you under that Access umbrella. If something happens, you have access to rehab professionals that can come in and do virtual care and also hands-on care because we have a physical network in the U.K. and we also have a partnership with some of the biggest care providers in the U.K. for that part of it. A very, very interesting journey to have been on for the last few months. In terms of narrative and in terms of visuals, we are very human-centric in the way that we are communicating this, because we are dealing with something that's set to prevent injuries and things like that to happen, but also to increase overall well-being. We have worked with some excellent branding consultants that have helped us developed this very human-centric, culture-building, habit-forming narrative, which has been a pure pleasure to market test over the last few weeks. A lot of exciting things coming based on the Axis ecosystem, starting in the Nordics and later in the U.K. Final slide here, just reiterating our financial goals. Top line growth 30% in the medium term. This is not something we plan to abandon anytime soon. In terms of profit margins, same thing there, 40%-45% in the medium term. Very achievable. However, keep in mind that as we acquire businesses and we work through them to enhance them, to accelerate them, we have to accept a little bit of pressure on our margins. In the medium term, we expect that we can clock in at the similar type of margins that Physitrack historically have been in, which is in the 40%-45% range and higher. Lastly, no dividend distribution is expected, but those of you who know us, we have communicated that we think that healthy, profitable companies should have a dividend agenda, and we do have that, just not in the medium term because we will use our funds mainly for acquisitions. That concludes the presentation, and we are now happy to take questions. Thank you. If you do wish to ask a question, please press zero and one on your telephone keypad. If you wish to withdraw your question, you may do so by pressing zero and two to cancel. There will be a brief pause while questions are being registered. All right. There's also a chat box there if you want to shoot questions straight over to us. We are on standby. We received the first question via telephone line. It's from Joachim Gunell, DNB Markets. The line is now open. Please go ahead. Thank you for that. Good day, Henrik and Charlotte. Obviously, I have a number of questions and operator, if there are anybody else in the queue, let me know and I'll get back to it too. Starting off, I mean, when we think about land and expand, so to say, can you talk us through here what you see here in terms of the number of products that your existing customers are buying? Obviously, we have seen some quite good momentum in the custom app sales as of late, but perhaps more from a broader perspective on the trajectory to getting existing customers to buy and subscribe to more products on your platform. Yeah. Thank you, Joachim. We stand on mainly four legs when it comes to the Physitrack platform. You have the platform itself or the subscription model, with access to clinical content and the outcome measures and things like that. Now we have the second leg, which is the specialised telehealth. The third leg is data repository products or data analysis product in the PhysiData range, and the fourth one is the Custom App range. Now we see activity across all these four. There is a systematic effort at pushing or introducing these products to notably RFP processes or request for proposal processes for enterprises, because it is usually you have a need for a holistic solution as an enterprise within those four areas. That's actually one of our competitive edges that we actually have very, very strong products in all those four. It is a systematic sales effort on that side. Now, there are trends in that we see in the marketplace where people need to catch up to needs that have been introduced by notably the macro environment. In the U.S., a few years ago, the trend towards outcome analysis and data analysis was very strong following Medicare and Medicaid initiatives to give bonuses for providing outcomes data into public healthcare systems, for example. Then you saw a boost for the PhysiData range. Obviously in 2020, you saw a big boost for telehealth and this year the big boost is on the Custom App side. There's some variation in that, but the process for pushing that out is always very systematic. Now obviously we will have a fifth leg. It'd be a very stable chair to sit on with e-learning that can form some very attractive bundles. There is nobody in the market that has that type of product range. With the experience also that we have with selling a whole custom... Oh, sorry, a whole range of products to a customer. We think that addition is gonna be a pretty natural one to our sales team to accelerate with. I hope that answers the question. A bsolutely. We can actually stay on the recently announced acquisition. When it comes to, I mean, PTcourses.com, can you just help us understand what is the growth profile of that business? That it expands your platform capabilities makes sense, I think. I mean, what are the hurdles to basically roll that U.S.-based e-learning offering out in key or existing markets? Also, I mean, you say that you see an opportunity to perhaps not entirely close the gap, but at least come closer to your target, the margin profile on the group business. What needs to basically materialize for those things to happen? That business is, it's a healthy business in and of its own. I think the business development tools that we can provide as a quite sophisticated group for digital health can help boost PT Courses quite significantly. We also think that there's a lot of talent that we have uniquely with Physitrack in terms of technology development to help step that platform up and make it more sophisticated. We have quite deep experience in e-learning, and actually notably, our CFO, Charlotte Goodwin, she actually came from a listed e-learning company. There are some great synergies with existing know-how that we can push into that to make that grow on a standalone basis. Obviously the bundle situation is the most important part of this. The objective is to achieve a seamless integration of PT Courses into the Physitrack platform so that you have this seamless, holistic experience with exercise prescription and the other components that we have, and it floats nicely into what you have to think about day to day as a healthcare provider that needs to do continuing education. I would say that the short-term effects from this will be visible on the Physitrack side because PT Courses has a very big customer base, and we will be able to very quickly come out and do things like, you know, offering discounts for the Physitrack platform. There's quite wide penetration in the U.S. with that, over 47 states. I think we can quite quickly see some effects there. In terms of the enterprise effects, I think we can expect probably around, say six to nine months before we have something that is on par with competitors in the U.S. in terms of bundles. There's a bit of a technology enhancement that needs to be done, and some integrations. Once this is done, because of our presence, and we are quite known as a brand in the U.S. market, we see that the acceleration of this in the enterprise space with RFPs can come relatively quickly. I think, within a 12-month period, we should probably have some quite nice effects over time. Now in terms of margins, we will of course look at PT Courses in that business. I mean, it's run by some very clever entrepreneurs that will stay with us for a while. I actually think that business is quite healthy as it is, so we will enhance that a little bit in terms of humans from the Physitrack side that will come in and help accelerate and grease the wheels, and then to pull out the best ideas from everybody. But overall, I think that we won't be seeing any cost synergies on the PT Courses side while we go through the transition situation here with the integration. Where we'll see margins expand mainly based on revenue acceleration at that end. Obviously on the Physitrack side, it will help fuel global growth. Now, last part of your question, international exposure with PT Courses. About 5% of PT Courses' customer portfolio is based on non-U.S. There's a little bit of exposure in the U.K., Australia, and in some other geos. We will take a look there to see what we can do to push some activity over to PT Courses based on that. That is quite exciting. It's not right on top of the agenda because the U.S. market is just very lucrative. It's something that we had planned for a very long time, ever since 2017, so that will remain the priority. I think if we do a good job in the U.S., there will be some interesting ripple effects in terms of revenue generation in other geos where we are present and very strong. Overall, very, very positive for us. I think, hope that covers it, Joachim. Yeah, no, absolutely. Thanks. Perhaps a question to Charlotte on the acquisition topic here. Can you say anything about how this will impact, say, number of users? Then perhaps more in particular, I mean, how will this impact D&A, which we have seen, call it, a slight step up now in recent quarters following recent acquisitions? Sorry, I heard the first bit, but the second bit, do you mind just repeating the second part of that question? You just dropped out for me for a second. Yes. How will this acquisition impact the amortization of intangible assets? Understood. Got you. Perfect. Well, I'll start at the end there. On the development side, I've messaged there that there will be around $600,000 spent, as Henrik talked about, that are from integration with the Physitrack platform. I would say that roughly half of that will be put to the balance sheet, so as a development as opposed to P&L. You'll see a little uptick in the amortization there, but nothing hugely significant. The remaining will be put through as adjusting items as a P&L cost. On the user question, well, as we've indicated, PT Courses has access to a list of over 60,000 U.S. practitioners, so we'll obviously be targeting that. We would expect to see that drive an increase in our user base. Understood. No, that's helpful. With regards to users or practitioners in the current Physitrack SaaS offering, can you say anything about, I mean, what particular markets or regions is driving growth in this quarter? North America has been very strong. Australia has also been very strong. Actually, the U.K., so the Anglo markets have been really the strongest markets. In the U.K., interestingly, there's a lot of new budgets in the NHS, the public healthcare system. There's a lot of investment, and we are increasing our footprint there. We were already a dominant player in the U.K. in public healthcare with Physiotools and Physitrack, and this is becoming more evident now. We actually see very strong growth with both products, Physitrack and Physiotools. U.K. extremely interesting. North America, notably Canada, also incredibly strong. Anglo markets, and then closely followed by our old friend, the Netherlands, where we've been present ever since inception in 2014. Understood. No, I mean, that's interesting. Can you say anything about when it comes to, I mean, call it growth strategy here? I mean, it's not that I mean you haven't for that long time now really ramped up this virtual care business, and obviously it consists of two acquisitions as of quite late. Can you say how the whole, like, virtual care venture, if I can call it that, has performed in relation to the expectations you had, call it, a year ago? Charlotte, we have some very nice growth numbers. I think we've been pleasantly surprised by especially the Nordic footprint there with the Fysiotest. I think they've done a terrific job of growing that business. Charlotte, if you wanna maybe give some data there, that'd be great. Yeah, definitely. You know, I think both of our care businesses have performed really well and in line with our expectations. Rehabplus is still a little bit driven by sort of return to normality with COVID, because a lot of its work's driven by things like operations happening as usual and as expected, and people being out and about and doing things to get injuries. We saw a little bit of a drop back during Omicron, there, but that's nicely looking like it's heading in the right direction again. That's all in line with expectations. Henrik, as Henrik says, I think with Fysiotest, we've been pleasantly surprised actually on the upside there, although it's still early days. We've seen great growth from the existing businesses, and I think as you've seen a little snippet there with Access that a lot of the good stuff is still to come, will come when we take all those capabilities, combine them with our tech, and launch some new and exciting products in that area. Yes. I think just looking at the numbers and what we've achieved, I think it's safe to say that we actually have been very successful in moving into that space. I'm happy to see that entrepreneurial mindset and the culture that those companies represent, that's matched very, very well with the entrepreneurial mindset and the culture that we have at Physitrack overall. Some great innovation collaborations and overall acceleration across that business line as well. Perfect. Without, I mean, really jumping the gun here when it comes to, I mean, the Access virtual care offering, can you say anything about, I mean, when you expect this to, I mean, to have like a fully commercially viable offering targeting employers here? Is it within this coming year, or is this more of a call it 2023 vision? No, it's definitely not a 2023 vision. This is something that we have because we are already present in prevention and wellness for corporates in the Nordics via Fysiotest. Very successful business that has mainly relied on local presence and then some virtualization. Access is actually the overall methodology with that ecosystem, and the tech is actually based on their commercial activities and their use case. We expect to have client exposure with that already in Q1, very carefully starting to dabble there with the commercial viability of it. The product is more or less done. The narrative is done as you've seen some examples on. It's very much a near-term situation in terms of market introduction. Now, in terms of acceleration, we want to be a little bit careful in terms of changing guidance for how we see care developing. The indications that we've had from the market and the interest that we have in this would indicate that this could potentially be something very substantial for us across the group. We're taking baby steps into that with commercialization here in Q1, and we'll just take it from there. That sounds very interesting. The final one for me for this time, we've discussed, I mean, call it a competitive landscape, et cetera, in the past. As we move further away or slightly at least away from the pandemic, have you seen any qualitative changes in terms of competitive landscape shifts? And how do you expect the landscape to change over the coming years, say? On the SaaS side, there hasn't really been any major movement. I think if there's been any movement, it's been led by us, in terms of, you know, what we've done with Physiotools and building the biggest clinical exercise library in the world and what we've been able to achieve there in terms of market footprint and also digitizing or just having the small to mid-size customer base of ours step up with Custom App setup. That's quite unique to us, so we haven't really seen any move there by anybody else. Obviously, our move today with the acquisition of PT Courses in the U.S., we think, will give a few players over there that have relied on quite expensive software bundles for their success, combining e-learning with home exercise prescriptions. We expect to give those guys a good run for their money in the coming quarters. Now, if you look at the care provision side of things, there's obviously a lot of movement there, and you see a lot of investments. There's nobody specifically that stands out in terms of this niche focus on something that combines emotional well-being and musculoskeletal well-being and rehab. There's nothing in Europe that just pops out. We do expect a lot of movement there over the coming quarters. I think it's a healthy sign that you start to have competition coming out because that means that there is a market for it, and there's a lot of appetite. I think we're extremely well-placed with the tech that we have, the product offering that we have, and the people that we have on board that have come in mainly through an M&A process. I think we're in pole position there when it comes to the European expansion there, notably with Access. Okay. Thank you. That's all from me for this time. Have a good day. Thank you, Joachim. Okay, we had a couple of questions here on the chat. In terms of Access, please elaborate around the pricing model. This is based on a subscription model that's based on the size of the company. It's scalable based on the number of employees that you have in a company. It's a flat- fee subscription model. And it's set to make rehab prevention and wellbeing costs very predictable and stable, so similar to buying subscription technology in other places where there is B2B or B2C. There has been a lot of demand for these type of things as the world has moved over to value-based healthcare, and there's a— It was just a question of time before this was gonna come to the prevention, wellness, and rehab space within predominantly MSK, musculoskeletal, and emotional wellbeing. Yeah, so I think that explains that. Another question here, could you give a hint about how Q1 2022 started? It started very well, thank you. We are excited with the opportunity set that we are faced with. There's nothing that's changed fundamentally in terms of what is out there in terms of enterprise activity for purchasing. Same thing there with small to mid-sized companies coming out of the pandemic led by Omicron, I should say, has actually had things return more or less to normal in terms of the care activity of first of all our customers, but also for our own care business. That's actually nice to see, and that's also driving investment. As people need to be less protective of their investment portfolios or their capital because they know that there's light at the end of the tunnel, there's more money coming into digital health, and that's been quite favorable for us. We saw that notably in Q4. There's no really slowdown that we can expect here. Can we expect any more acquisitions in Q1? We'll just have to wait and see. There are a lot of interesting things going on, obviously, and yeah, a lot of smart people out there, healthy businesses that we're interested in. Stay tuned. Do you search for anything in Japan and South Korea? Well, actually, we have more or less fully localized SaaS tech for Japan and South Korea. We're a little bit on standby just to see what we want to do there. It's mainly related to recruitment. We'll see what comes up. We're quite interested in both those geos, and we have technology that's more or less ready to go there. How fast do you think the implementation of PT Courses can go? Well, you will see. I think I explained that a little bit on Joachim. In terms of offering, doing some quick, you know, campaigns and offering some discounts on Physitrack for PT Courses customers, I think that can be very quick. So there's a big customer database, and they would love to have access to Physitrack at a nice price point. So that we'll probably see a little bit of that just following the acquisition. In terms of the deeper integration, we will phase that. You'll start with things like very simple single sign-on, login, so that just to make it easy to use those two systems in parallel. Step by step, you will see a more seamless inclusion of PT Courses inside of Physitrack, and vice versa. Eventually, the vision is that it doesn't matter if you're a PT Courses customer. You can log into that, and you can use Physitrack seamlessly inside that. Or if you log into Physitrack, you can conversely use PT Courses. Obviously some enhancements along the way that we'll be doing just to catch up a little bit with the U.S. market space. We have a 12-month horizon on the full integration of PT Courses. As we said, we will see things step by step rolling into that. I think that concludes the question battery on the chat. Was there anybody else on the phone? No, we haven't received any further questions via the telephone line. Okay, very good. Okay, we are ready to wrap up. Thank you so much for attending, everybody. This call will be available on replay on physitrackgroup.com. Thank you so much, and have a lovely day.